Skip to main content

CORRECTION article

Front. Oncol., 22 January 2024
Sec. Gynecological Oncology
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1357793

Corrigendum: Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors

This article is a correction to:

  1. Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors

    1. Read original article
Francesca Arezzo,Francesca Arezzo1,2Gaia Giannone*Gaia Giannone3*Daniele CastaldoDaniele Castaldo4Giulia ScottoGiulia Scotto5Valentina TuninettiValentina Tuninetti6Margherita TurinettoMargherita Turinetto5Michele BartolettiMichele Bartoletti7Serafina MammolitiSerafina Mammoliti8Grazia ArtioliGrazia Artioli9Giorgia MangiliGiorgia Mangili10Vanda SalutariVanda Salutari11Domenica LorussoDomenica Lorusso12Gennaro Cormio,Gennaro Cormio1,13Vera Loizzi,Vera Loizzi1,13Claudio ZamagniClaudio Zamagni14Antonella SavareseAntonella Savarese15Massimo Di MaioMassimo Di Maio6Graziana RonzinoGraziana Ronzino16Carmela PisanoCarmela Pisano17Sandro PignataSandro Pignata17Giorgio ValabregaGiorgio Valabrega6
  • 1Gynecologic Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy
  • 2Department of Precision and Regenerative Medicine – Ionian Area, University of Bari “Aldo Moro”, Bari, Italy
  • 3Department of Surgery and Cancer, Imperial College London, London, United Kingdom
  • 4Segreteria Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) Group, Naples, Italy
  • 5Department of Oncology, University of Turin, Turin, Italy
  • 6Department of Oncology, Mauriziano Hospital, University of Turin, Turin, Italy
  • 7Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy
  • 8Ospedale Policlinico San Martino - Department of Medical Oncology, IRCCS, Genoa, Italy
  • 9Oncologia Medica, Unità locale socio sanitaria n2 (ULSS2) Marca Trevigiana, Treviso, Italy
  • 10Obstet-Gynecol Department, San Raffaele Scientific Institute, IRCCS, Milan, Italy
  • 11Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
  • 12Department of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli, and Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
  • 13Interdisciplinar Department of Medicine, University of Bari “Aldo Moro”, Bari, Italy
  • 14Azienda Ospedaliero-universitaria di Bologna, IRCCS, Bologna, Italy
  • 15Department of Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
  • 16Department of Oncology, Ospedale “Vito Fazzi”, Lecce, Italy
  • 17Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Napoli, Naples, Italy

A Corrigendum on
Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors

by Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetto M, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutari V, Lorusso D, Cormio G, Loizzi V, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S and Valabrega G (2023) Front. Oncol. 13:1247291. doi: 10.3389/fonc.2023.1247291

In the published article, there was an error in affiliation 15. Instead of “Department of Oncology, Regina Elena National Cancer Institute, Rome, Italy”, it should be “Department of Oncology, IRCCS Regina Elena National Cancer Institute-Rome, Italy.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: endometrial cancer, molecular classification, immune checkpoint inhibitors, dostarlimab, pembrolizumab plus lenvatinib

Citation: Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetto M, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutari V, Lorusso D, Cormio G, Loizzi V, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S and Valabrega G (2024) Corrigendum: Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors. Front. Oncol. 13:1357793. doi: 10.3389/fonc.2023.1357793

Received: 18 December 2023; Accepted: 19 December 2023;
Published: 22 January 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Arezzo, Giannone, Castaldo, Scotto, Tuninetti, Turinetto, Bartoletti, Mammoliti, Artioli, Mangili, Salutari, Lorusso, Cormio, Loizzi, Zamagni, Savarese, Di Maio, Ronzino, Pisano, Pignata and Valabrega. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Gaia Giannone, Zy5naWFubm9uZUBpbXBlcmlhbC5hYy51aw==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.